From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)
 | JIA (N=121) | p |
---|---|---|
MTXO: MTXSC, n | 45 : 76 | Â |
MTX dose, median (IQR) mg/m2/week | 9.7 (9.0 – 10.9) | - |
 MTXo : MTXSC | 9.6 (9.0-10.7) : 9.8 (8.8-11.1) | 0.86 |
MTX treatment duration, median (IQR)Â days | 340 (142-766) | - |
 MTXo : MTXSC | 261 (143-543) : 417 (134-853) | 0.39 |
BAI-Y raw score (total 0 – 60), mean (95%CI) | 27.4 (26.2 – 28.6) | - |
 MTXintol : MTXtol(MISS) | 27.8 (26.1-29.4) :26.9 (25.3-28.6) | 0.48 |
 MTX-induced nausea: All others (Diary) | 28.0 (26.3-29.6) : 24.4 (22.8-26.0) | 0.0024 |
Unfavourable Coping Strategies[1], mean (95% CI) | 16.5 (15.5-17.5) | - |
 MTXintol : MTXtol (MISS) | 17.3 (15.9-18.7) :15.2 (13.8-16.5) | 0.0287 |
 MTX-induced nausea: All others (Diary) | 17.7 (16.2-19.3) :13.0 (11.6-14.4) | <0.0001 |